Structured around development to commercial application of musculoskeletal regenerative therapies for osteoarthritis, the principals of Regenosine have effectively demonstrated that restoring adenosine levels in various tissue types can induce tissue regeneration. The company-developed therapies use a purinergic system that regulates and maintains tissue homeostasis and restores adenosine levels, enabling users to harness the healing potential of adenosine for tissue regeneration. he firm's proprietary platform technology effectively plays a critical role in maintaining cartilage homeostasis. The firm's lead product is a proprietary formulation for regenerating cartilage in joints with established osteoarthritis - targeted at a rapidly growing joint preservation market. The firm's business objective is to offer a disease modifying therapy with uncompromising efficacy relative to existing technologies. Development of a disease modifying therapy of this type could both significantly improve clinical outcomes and patient quality of life while also reducing the total health care delivery costs associated with osteoarthritis.
